Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer

Clinical Biochemistry

Volumn 47, Issue 7-8, 2014, Pages 612-617

  Qiu, Hao ^a   Zheng, Liang ^b   Tang, Weifeng ^c   Yin, Pengfei ^a   Cheng, Feng ^a   Wang, Lixin ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Esophageal cancer; Molecular epidemiology; PD 1; Polymorphisms; Susceptibility

Indexed keywords

LIGASE; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENDER; GENE CONTROL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIGASE CHAIN REACTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84900321978     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.12.023     Document Type: Article

References (42)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Chen W., He Y., Zheng R., Zhang S., Zeng H., Zou X., et al. Esophageal cancer incidence and mortality in china, 2009. J Thorac Dis 2013, 5:19-26.
3. Gholipour C., Shalchi R.A., Abbasi M. A histopathological study of esophageal cancer on the western side of the caspian littoral from 1994 to 2003. Dis Esophagus 2008, 21:322-327.
4. Tran G.D., Sun X.D., Abnet C.C., Fan J.H., Dawsey S.M., Dong Z.W., et al. Prospective study of risk factors for esophageal and gastric cancers in the linxian general population trial cohort in China. Int J Cancer 2005, 113:456-463.
5. Wu C., Hu Z., He Z., Jia W., Wang F., Zhou Y., et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 2011, 43:679-684.
6. Sharpe A.H., Wherry E.J., Ahmed R., Freeman G.J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007, 8:239-245.
7. James E.S., Harney S., Wordsworth B.P., Cookson W.O., Davis S.J., Moffatt M.F. Pdcd1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun 2005, 6:430-437.
8. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. Pd-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
9. Gao Q., Wang X.Y., Qiu S.J., Yamato I., Sho M., Nakajima Y., et al. Overexpression of pd-l1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009, 15:971-979.
10. Karim R., Jordanova E.S., Piersma S.J., Kenter G.G., Chen L., Boer J.M., et al. Tumor-expressed b7-h1 and b7-dc in relation to pd-1+ t-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009, 15:6341-6347.
11. Hua D., Sun J., Mao Y., Chen L.J., Wu Y.Y., Zhang X.G. B7-h1 expression is associated with expansion of regulatory t cells in colorectal carcinoma. World J Gastroenterol 2012, 18:971-978.
12. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11:2947-2953.
13. Zeng Z., Shi F., Zhou L., Zhang M.N., Chen Y., Chang X.J., et al. Upregulation of circulating pd-l1/pd-1 is associated with poor post-cryoablation prognosis in patients with hbv-related hepatocellular carcinoma. PLoS One 2011, 6:e23621.
14. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007, 13:2151-2157.
15. Blank C., Mackensen A. Contribution of the pd-l1/pd-1 pathway to t-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007, 56:739-745.
16. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., Mcdermott D.F., et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
17. Zhou Q., Munger M.E., Highfill S.L., Tolar J., Weigel B.J., Riddle M., et al. Program death-1 signaling and regulatory t cells collaborate to resist the function of adoptively transferred cytotoxic t lymphocytes in advanced acute myeloid leukemia. Blood 2010, 116:2484-2493.
18. Kang M.J., Kim K.M., Bae J.S., Park H.S., Lee H., Chung M.J., et al. Tumor-infiltrating pd1-positive lymphocytes and foxp3-positive regulatory t cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 2013, 6:282-289.
19. Foureau D.M., Mckillop I.H., Jones C.P., Amin A., White R.L., Salo J.C. Skin tumor responsiveness to interleukin-2 treatment and cd8 foxp3+ t cell expansion in an immunocompetent mouse model. Cancer Immunol Immunother 2011, 60:1347-1356.
20. Shi F., Shi M., Zeng Z., Qi R.Z., Liu Z.W., Zhang J.Y., et al. Pd-1 and pd-l1 upregulation promotes cd8(+) t-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011, 128:887-896.
21. Malaspina T.S., Gasparoto T.H., Costa M.R., de Melo E.F., Ikoma M.R., Damante J.H., et al. Enhanced programmed death 1 (pd-1) and pd-1 ligand (pd-l1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011, 60:965-974.
22. Shimauchi T., Kabashima K., Nakashima D., Sugita K., Yamada Y., Hino R., et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic cd4+ t-cells in adult t-cell leukemia/lymphoma. Int J Cancer 2007, 121:2585-2590.
23. Zlobec I., Karamitopoulou E., Terracciano L., Piscuoglio S., Iezzi G., Muraro M.G., et al. Tia-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of cd8 in mismatch repair-proficient colorectal cancer. PLoS One 2010, 5:e14282.
24. Wang B.J., Bao J.J., Wang J.Z., Wang Y., Jiang M., Xing M.Y., et al. Immunostaining of pd-1/pd-ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011, 17:3322-3329.
25. Piskin I.E., Calik M., Abuhandan M., Kolsal E., Celik S.K., Iscan A. Pd-1 gene polymorphism in children with subacute sclerosing panencephalitis. Neuropediatrics 2013, 44:187-190.
26. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V., et al. A regulatory polymorphism in pdcd1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666-669.
27. Qian B.P., Wang X.Q., Qiu Y., Jiang H., Ji M.L., Jiang J. An exon polymorphism of programmed cell death 1 gene is associated with both the susceptibility and thoracolumbar kyphosis severity of ankylosing spondylitis in a Chinese Han population. J Orthop Sci 2013, 18:514-518.
28. Bertsias G.K., Nakou M., Choulaki C., Raptopoulou A., Papadimitraki E., Goulielmos G., et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009, 60:207-218.
29. Tahoori M.T., Pourfathollah A.A., Akhlaghi M., Daneshmandi S., Nicknam M.H., Soleimanifar N. Association of programmed cell death-1 (pdcd-1) gene polymorphisms with rheumatoid arthritis in iranian patients. Clin Exp Rheumatol 2011, 29:763-767.
30. Flores S., Beems M., Oyarzun A., Carrasco E., Perez F. Programmed cell death 1 (pdcd1) gene polymorphisms and type 1 diabetes in chilean children. Rev Med Chil 2010, 138:543-550.
31. Qi P., Dou T.H., Geng L., Zhou F.G., Gu X., Wang H., et al. Association of a variant in mir 196a2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis b virus infection. Hum Immunol 2010, 71:621-626.
32. Cheng X.L., Ning T., Xu C.Q., Li Y., Zhu B.S., Hou F.T., et al. Haplotype analysis of ctla4 gene and risk of esophageal squamous cell carcinoma in Anyang area of China. Hepatogastroenterology 2011, 58:432-437.
33. Sun T., Zhou Y., Yang M., Hu Z., Tan W., Han X., et al. Functional genetic variations in cytotoxic t-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68:7025-7034.
34. Li Z., Li N., Zhu Q., Zhang G., Han Q., Zhang P., et al. Genetic variations of pd1 and tim3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infect Genet Evol 2013, 14:240-246.
35. Bennet A.M., Alarcon-Riquelme M., Wiman B., de Faire U., Prokunina-Olsson L. Decreased risk for myocardial infarction and lower tumor necrosis factor-alpha levels in carriers of variants of the pdcd1 gene. Hum Immunol 2006, 67:700-705.
36. Spielman R.S., Bastone L.A., Burdick J.T., Morley M., Ewens W.J., Cheung V.G. Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 2007, 39:226-231.
37. Hua Z., Li D., Xiang G., Xu F., Jie G., Fu Z., et al. Pd-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of northeast China. Breast Cancer Res Treat 2011, 129:195-201.
38. Majewski J., Ott J. Distribution and characterization of regulatory elements in the human genome. Genome Res 2002, 12:1827-1836.
39. Gazave E., Marques-Bonet T., Fernando O., Charlesworth B., Navarro A. Patterns and rates of intron divergence between humans and chimpanzees. Genome Biol 2007, 8:R21.
40. Balvay L., Libri D., Fiszman M.Y. Pre-mRNA secondary structure and the regulation of splicing. Bioessays 1993, 15:165-169.
41. Braddock M., Muckenthaler M., White M.R., Thorburn A.M., Sommerville J., Kingsman A.J., et al. Intron-less RNA injected into the nucleus of xenopus oocytes accesses a regulated translation control pathway. Nucleic Acids Res 1994, 22:5255-5264.
42. Baralle D., Baralle M. Splicing in action: assessing disease causing sequence changes. J Med Genet 2005, 42:737-748.